About the study

Testing for inherited susceptibility to cancer has been available for over 20 years, but uptake remains low among even patients at high risk. It is now well-established that between 1 in 5 and 1 in 20 patients with breast, ovarian, endometrial or colorectal cancers has a deleterious germline mutation conferring inherited susceptibility to cancer.

Despite advances in genetic testing technologies and a decrease in the cost of testing, the uptake of testing among eligible patients with cancer remains unacceptably low. There is thus a gap between actual and ideal care with implications for primary and secondary cancer prevention and treatment in people with an inherited susceptibility and their family members.

The MiGHT study leverages diverse, statewide partnerships among healthcare and public health entities to employ both practice- and patient-level interventions to improve family history collection and uptake of genetic testing, with the overarching goal of reducing cancer morbidity and mortality.


Michigan Oncology Quality Consortium (MOQC) logo

Michigan Oncology Quality Consortium

Michigan Department of Health and Human Services logo

Michigan Department of Health and Human Services Cancer Genomics Branch

Michigan Genetic Hereditary Testing logo

Advisory Board

Our Advisory Board is made up of key stakeholders across the state including patients, oncologists, genetic counselors, and practice administrators. The board was formed in order to ensure all aspects of the MiGHT project are informed by patients and practices. Our current board members are:

Helen Burns

Cynthia Koch

Nancie Petrucelli

Dana Zakalik

Monica Dottei

Kathy LaRaia

Tina Roberts

Jo Ann Hirth

Daniel “Dry Dock” Shockley

Laura Wangler

Laura Johnson

Kevin Myers

Bob Whalen

Corrie Bourdon

Cheryl Verstrate

Tracey Cargill-Smith